Product Portfolio
GCAT seeks to build its portfolio by acquiring and in-licensing proprietary products from North America and EU in the areas of cancer, cardiovascular disease, neurology, infectious diseases and immunology. Its’ Chinese based partners and team will manage clinical development and regulatory approval as well as providing complete sales and marketing support.
